Oculus Innovative Sciences, Inc. to Announce Additional Phase II Data and Data from Two Recent International Studies at DFCon 08

PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) announced that it will host a webcast and teleconference at 9:30 a.m. PDT (12:30 p.m. EDT) on Friday, March 14, 2008, to announce additional data from the Phase II clinical trial of Microcyn Technology in patients with mildly infected diabetic foot ulcers. Additionally, supporting results from two international studies of Microcyn Technology, completed in Italy and India, will be presented as well. The presentation follows the company’s recent announcement of positive top-line data from the Phase II study released on February 27, 2008. For more information on the top-line data, please refer to the press release posted at http://www.oculusis.com/phase2data.

Back to news